USGIU
BIS icon

U.S. Global Investors (USGI)’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

U.S. Global Investors (USGI)’s Portfolio BIS Stock Details BIS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-250
Closed -$79K – 153
2016
Q3 		$79K Buy
+250
New +$66.4K 0.04% 139

Other funds holding BIS

TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

U.S. Global Investors (USGI)'s BIS Position: Q4 2016 in Review

U.S. Global Investors (USGI) sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q4 2016, closing a stake of 250 shares — an estimated $79K sold.

U.S. Global Investors (USGI) first reported a position in BIS in Q3 2016 and held it in 1 quarter. The position peaked at $79K in Q3 2016. 13 funds tracked by Wall St. Rank hold BIS as of Q4 2016.

  • U.S. Global Investors (USGI) reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q4 2016 after selling out during the quarter.
  • U.S. Global Investors (USGI) sold 250 ProShares UltraShort NASDAQ Biotechnology shares in Q4 2016, an estimated $79K.
  • U.S. Global Investors (USGI) first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q3 2016 and held it in 1 quarter.
  • U.S. Global Investors (USGI)'s ProShares UltraShort NASDAQ Biotechnology position peaked at $79K in Q3 2016.
  • 13 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q4 2016.

Based on U.S. Global Investors (USGI)'s 13F filing for Q4 2016, filed 14 Feb 2017.